Effect of topical antiglaucoma medications on prevention for intraocular pressure elevation after cataract surgery in eyes with glaucoma : a randomized clinical comparative study.

Effect of topical antiglaucoma medications on prevention for intraocular pressure elevation after cataract surgery in eyes with glaucoma : a randomized clinical comparative study. - Topical antiglaucoma agents against IOP elevation after cataract surgery

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000034416

Enrollment

165

Registered

2018-10-09

Start date

2016-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Open-angle glaucoma

Interventions

55 eyes of 55 patients who received topical prostaglandin F2A analogue just after surgery (Travoprost 0.004%, Travatanz

Alcon Pharmaceutical

Fort Worth, TX, USA). 55 eyes of 55 patients who received topical B-blocker just after surgery (0.5% Timolol maleate, Timoptol

Santen Pharmaceutical, Tokyo, Japan). 55 eyes of 55 patients who received topical carbonic anhydrase inhibitor (CAI) just after surgery (Brinzolamide 2%, Azopt

Alcon).

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Clinical research coordinators began screening of all consecutive eyes with medically well-controlled POAG or pseudoexfoliation glaucoma with topical antiglaucoma agents (an IOP of 21 mmHg or less at 2 continuous prior visits) that were scheduled for phacoemulsification with implantation of a hydrophobic acrylic intraocular lens (IOL).

Exclusion criteria

Exclusion criteria: Exclusion criteria were 1) eyes with any ocular pathology other than cataract and glaucoma; 2) eyes scheduled for planned extracapsular or intracapsular cataract extraction; 3) history of previous ocular surgery or inflammation; 4) patients with contraindication for administration of prostaglandin F2A analogues, B-blockers, topical carbonic anhydrase inhibitor; 5) patient refusal; 6) any anticipated difficulties with examination or follow-up; and 7) patients who were included in another study.

Design outcomes

Primary

Measure	Time frame
IOP was measured using a rebound tonometer at 1 hour preoperatively; at the end of surgery (surgically adjusted to range between 15 and 25 mmHg); and at 2, 4, 6, 8, and 24 hours postoperatively.	—

Secondary

Measure	Time frame
1) Static visual fields sensitivity with 30-2 program of the Humphrey Field Analyzer. 2) Flare intensity at 6 hours after surgery 3) Wound states determined using anterior segment-optical coherence tomography 4) Visual acuity, refraction, corneal astigmatism	—

Countries

Japan

Contacts

Public ContactKen Hayashi

Hayashi Eye Hospital Department of Ophthalmology

hayashi-ken@hayashi.or.jp092-431-1680

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026